Aliases:This biomarker is also known as:
- CAM 120/80,
- cadherin 1, type 1, E-cadherin (epithelial),
The CDH1 gene is a classical cadherin from the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. CDH1 has a potent invasive suppressor role.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
Cadherins are cell-cell adhesion molecules. Lower levels of cadherins, particulary CDH1 (E-cadherin), can cause the cell to be unable to adhere, resulting in a loss of the normal architecture of tissues. This effect has been seen with CDH1 and lung cancer.
CDH1 has been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker. It has also been suggested as a biomarker to differentiate between bronchioloalveolar carcinoma and conventional pulmonary carcinoma, and between mesothelioma and metastatic pulmonary adenocarcinoma. CDH1 is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.
|QA State:||Under Review|
- An epigenetic marker panel for detection of lung cancer using cell-free serum DNA.
- The state of molecular biomarkers for the early detection of lung cancer.
- Cadherin superfamily of adhesion molecules in primary lung cancer.
- Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.